Month: May 2022
Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
By Juniper Biologics
/
May 4, 2022
/
Comments Off on Juniper Biologics signs exclusive license agreement with Helsinn for infigratinib (INN) for the emerging markets*
Juniper Biologics Pte Ltd announced today the signing of an exclusive license agreement to develop and commercialise infigratinib (INN) in Australia, New Zealand, Southeast Asia and certain markets in the Middle East and Africa.
Read More